Header Logo

Connection

SUZANNE FUQUA to Cell Line, Tumor

Back to Details
This is a "connection" page, showing publications SUZANNE FUQUA has written about Cell Line, Tumor.
SUZANNE FUQUA
Connection Strength
0.814
Cell Line, Tumor
  1. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERa-positive breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):225-37.
    View in: PubMed
    Score: 0.071
  2. A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions. Breast Cancer Res Treat. 2010 Jul; 122(2):381-93.
    View in: PubMed
    Score: 0.047
  3. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat. 2010 Jan; 119(1):71-85.
    View in: PubMed
    Score: 0.045
  4. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther. 2006 Dec; 5(12):3023-31.
    View in: PubMed
    Score: 0.038
  5. Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol. 2006 Sep; 20(9):2020-35.
    View in: PubMed
    Score: 0.037
  6. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 2004 Dec 15; 64(24):9199-208.
    View in: PubMed
    Score: 0.034
  7. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
    View in: PubMed
    Score: 0.033
  8. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.033
  9. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.032
  10. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer. Cancer Res. 2024 01 16; 84(2):291-304.
    View in: PubMed
    Score: 0.032
  11. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
    View in: PubMed
    Score: 0.025
  12. Proteomic profiling identifies key coactivators utilized by mutant ERa proteins as potential new therapeutic targets. Oncogene. 2018 08; 37(33):4581-4598.
    View in: PubMed
    Score: 0.021
  13. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. 2018 08; 37(33):4489-4504.
    View in: PubMed
    Score: 0.021
  14. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
    View in: PubMed
    Score: 0.019
  15. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016 06; 157(2):253-265.
    View in: PubMed
    Score: 0.019
  16. Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res. 2016 04 01; 76(7):1942-53.
    View in: PubMed
    Score: 0.018
  17. Targeting thyroid hormone receptor beta in triple-negative breast cancer. Breast Cancer Res Treat. 2015 Apr; 150(3):535-45.
    View in: PubMed
    Score: 0.017
  18. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Res Treat. 2014 Jul; 146(2):273-85.
    View in: PubMed
    Score: 0.016
  19. In vitro mechanism for downregulation of ER-a expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol Nutr Food Res. 2013 May; 57(5):840-53.
    View in: PubMed
    Score: 0.015
  20. Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol. 2013 Jun; 7(3):379-91.
    View in: PubMed
    Score: 0.015
  21. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene. 2013 Jul 04; 32(27):3274-85.
    View in: PubMed
    Score: 0.014
  22. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 2012 Jun 14; 14(3):R95.
    View in: PubMed
    Score: 0.014
  23. Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat. 2012 Jul; 134(2):569-81.
    View in: PubMed
    Score: 0.014
  24. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res. 2012 Mar 15; 72(6):1416-27.
    View in: PubMed
    Score: 0.014
  25. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 2011 Dec 01; 71(23):7259-69.
    View in: PubMed
    Score: 0.013
  26. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res. 2011 Oct 15; 17(20):6510-21.
    View in: PubMed
    Score: 0.013
  27. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 2011 Oct; 25(10):3695-707.
    View in: PubMed
    Score: 0.013
  28. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene. 2011 Sep 29; 30(39):4129-40.
    View in: PubMed
    Score: 0.013
  29. Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
    View in: PubMed
    Score: 0.013
  30. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13.
    View in: PubMed
    Score: 0.013
  31. Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator. Mol Endocrinol. 2010 May; 24(5):914-22.
    View in: PubMed
    Score: 0.012
  32. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene. 2010 Apr 22; 29(16):2404-14.
    View in: PubMed
    Score: 0.012
  33. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol. 2010 Jan; 24(1):76-90.
    View in: PubMed
    Score: 0.012
  34. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol. 2009 Nov; 23(11):1815-26.
    View in: PubMed
    Score: 0.012
  35. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol. 2009 Sep; 175(3):1270-80.
    View in: PubMed
    Score: 0.012
  36. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
    View in: PubMed
    Score: 0.011
  37. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. Mol Endocrinol. 2009 Apr; 23(4):454-65.
    View in: PubMed
    Score: 0.011
  38. Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein. Cancer Res. 2005 Nov 15; 65(22):10594-601.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.